欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

Metabolic Disease

货号 产品名 CAS号 信息
CSN21104 Semaglutide 910463-68-2 Semaglutide is an analog of human GLP-1 with long-acting effect over the other GLP-1Ras.
CSN20202 BAR502 1612191-86-2 BAR502 is an agonist of FXR and GPBAR1 that promotes browning of white adipose tissue and reverses liver fibrosis and steatosis.
CSN20344 1-(2-Morpholinoethyl)-3-(4-(3-(6-morpholinopyridin-2-yl)acryloyl)phenyl)urea hydrochloride 1333327-56-2 TRC051384 is an inducer of heat shock protein Hsp70. it reduces stroke-associated neuronal injury and increases survival in a rat model of transient ischemic stroke and activates heat shock factor-1 and results in elevated chaperone and anti-inflammatory activity.
CSN20481 DC260126 346692-04-4 DC260126 is antagoniat of free fatty acid receptor 1 (FFA1/GPR40) and inhibits FFA-induced the increase of intracellular Ca2+ level.
CSN20554 Seladelpar 851528-79-5 Seladelpar is selectively exhibits activation of peroxisome proliferator-activated receptor δ (PPARδ) which may has therapeutic activity against dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis.
CSN20583 FIN56 1083162-61-1 FIN56 is a ferroptosis activator and glutathione peroxidase 4 (GPX4) degradation inducer. It also bound to and activated squalene synthase (SQS), an enzyme involved in isoprenoid biosynthesis.
CSN21217 MCH-1 antagonist 1 1039825-68-7 MCH-1 antagonist 1 is a potent melanin concentrating hormone (MCH-1) antagonist with a Ki of 2.6 nM. MCH-1 antagonist 1 also inhibits CYP3A4 with an IC50 of 10 μM.
CSN21110 MK-4074 1039758-22-9 MK-4074 is a liver-specific inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 values of approximately 3 nM.
CSN21231 MK-6913 1398510-92-3 Tetrahydrofluoroene 52 is a potent and selective estrogen receptor β agonist.
CSN21121 AK-1 330461-64-8 AK-1 is a cell permeable, benzylsulfonamide that inhibits SIRT2 activity (IC50= 12.5 µM through enzymatic assay) by targeting the SIRT2 nicotinamide binding site, but may also target SIRT1 and SIRT3 (IC50 >40 µM) with much less potency.
CSN21176 ALB-127158(a) 1173154-32-9 ALB-127158(a) is a potent and selective melanin concentrating hormone 1 (MCH1) receptor antagonist.
CSN21112 Licogliflozin 1291094-73-9 Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor
CSN21232 Firsocostat 1434635-54-7 ND-630 is an allosteric inhibitor of acetyl-CoA carboxylase (ACC) dimerization that inhibits ACC1 and ACC2 activity (IC50s = 2.1 and 6.1 nM, respectively, for the human enzymes).
CSN20651 AZD 4017 1024033-43-9 AZD4017 is a potent, selective, and orally bioavailable11β-HSD1 inhibitor (11β-hydroxysteroid dehydrogenase type 1 inhibitor). Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome.
CSN20272 27-Hydroxycholesterol 20380-11-4 27-Hydroxycholesterol is an endogenous oxysterol with multiple biological functions, including activity as a selective estrogen receptor modulator (SERM) (a mixed, tissue-specific agonist-antagonist of the estrogen receptor (ER)) and as an agonist of the liver X receptor (LXR). It is a metabolite of cholesterol that is produced by the enzyme CYP27A1.
CSN20345 TRC051384 867164-40-7 TRC051384 is a inducer of Hsp70.
CSN20633 SB-649868 380899-24-1 SB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist (pKi =9.4 and 9.5 at the OX1 and OX2 receptor, respectively).
CSN20422 Gemigliptin 911637-19-9 Gemigliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.
CSN20218 JD-5037 1392116-14-1 JD-5037 is a peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
CSN20177 Dorzagliatin 1191995-00-2 Dorzagliatin is a glucokinase activator on glucose metabolism.
CSN20285 Suksdorfin 53023-17-9 Suksdorfin promotes adipocyte differentiation and improves abnormalities in glucose metabolism via PPARγ activation.
CSN20634 Lapaquistat acetate 189060-13-7 Lapaquistat acetate is a squalene synthase inhibitor with cholesterol-lowering effect.
CSN20181 AMG131 315224-26-1 AMG-131 is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.
CSN20322 Prostaglandin D2 41598-07-6 Prostaglandin D2 is the major eicosanoid product of mast cells and is released in large quantities during allergic and asthmatic anaphylaxis.
CSN20466 L-798106 244101-02-8 L-798106 is a potent and highly selective prostanoid EP3 receptor antagonist (Ki values are 0.3, 916, > 5000 and > 5000 nM at EP3, EP4, EP1 and EP2, respectively), and it can attenuate sulprostone-induced inhibition of EFS-evoked twitch and contractile responses in vivo.
CSN20207 DGAT1 Inhibitor C9 1137671-16-9 DGAT1 inhibitor C9 is an orally bioavailable benzimidazole diacylglycerol acyltransferase 1 (DGAT1) inhibitor.
CSN20221 MK-2305 2101206-49-7 MK-2305 is a GPR40 partial agonist lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
CSN20222 BMS-816336 1009583-20-3 BMS-816336, a hydroxyl-substituted adamantyl acetamide, has been identified as a potent inhibitor against human 11β-hydroxysteroid dehydrogenase type 1(11β-HSD1) enzyme (IC50 3.0 nM) with > 10000 fold selectivity over human 11β-hydroxysteroid dehydrogenase type 2(11β-HSD2).
CSN20386 HBK001 1942922-78-2 HBK001 is a dual DPP4 inhibitor and GPR119 agonist that regulates glycemic control and beta cell function ex and in vivo.
CSN20374 GPR119 Agonist C26 1353004-92-8 GPR119 agonist C26 shows potent GPR119 agonistic activity (EC50 = 42 nM, Emax = 117%) with improved liver microsome clearance than other GPR119 agonists in the series, and exerted 33% reduction in blood glucose AUC at a dose of 10 mg/kg in an oral glucose tolerance test in C57BL/6 N mice.
CSN20397 VAP-1 Inhibitor C17h 1279026-89-9 VAP-1 inhibitor C17h is an orally active VAP-1 inhibitor, which can significantly inhibited the progression of proteinuria in streptozotocin (STZ) induced diabetic rats at 0.3 and 1 mg/kg, suggesting that this compound has potential to be a therapeutic agent for the treatment of diabetic nephropathy.
CSN20376 CKD-519 1402796-27-3 CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol.
CSN20491 Echinomycin 512-64-1 Echinomycin is a highly potent and selective HIF-1α inhibitor (IC50 = 29.4 pM) which selectively inhibits HIF-1 binding to the VEGF promoter without affecting the binding of AP-1 or NF-κB.
CSN20401 DS79182026 2113642-80-9 DS79182026 is a potent and bioavailable hepcidin production inhibitor, which showed serum hepcidin lowering effects in a mouse IL-6 induced acute inflammatory model.
CSN20318 SSTR5 Antagonist C3p 1628744-37-5 SSTR5 antagonist C3p is a SSTR5 antagonist with improved PK profile and hERG inhibition activity. It can successfully exhibited a persistent glucose-lowering effect in an OGTT at a dose of 3 mg/kg.
CSN20593 Henagliflozin 1623804-44-3 Henagliflozin is a sodium glucose co-tranporter 2 inhibitor, with the IC50 values against human SGLT2 and SGLT1 were 2.38 and 4324 nmol/L, respectively, and is used for treating patients with type 2diabetes mellitus.
CSN20588 Retagliptin 1174122-54-3 Retagliptin is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CSN20327 26-Deoxyactein 264624-38-6 27-Deoxyactein, a natural product isolated and purified from Actaea racemosa, has shown stimulation of osteoblast function and inhibits bone resorbing mediators in the treatment of osteoporosis. It is a derivative of actein, a gamma secretase modulators derived from botanicals. It can also protect the pancreatic β-cells against MG-induced cell death.
CSN20589 Retagliptin Hydrochloride 1174038-86-8 Retagliptin HCl is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CSN20626 TA-1887 1003005-29-5 TA-1887 is a highly potent and selective hSGLT2 inhibitor, with pronounced antihyperglycemic effects in high-fat diet-fed KK (HF-KK) mice.
CSN20590 Retagliptin phosphate 1256756-88-3 Retagliptin phosphate is a DPP-4 inhibitor potentially used for the treatment of Type 2 diabetes.
CSN20543 Evogliptin 1222102-29-5 Evogliptin is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) which improves insulin resistance and delays the onset of diabetes.
CSN20592 (Z)-5-(2-Hydroxy-3-(2-(3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H-pyrazol-4(5H)-ylidene)hydrazinyl)phenyl)furan-2-carboxylic acid 1257792-41-8 Hetrombopag ethanolamine is a thyroperoxidase (TPO) inhibitor potentially for the treatment of thrombocytopenia and a non-peptide small molecular TPO receptor agonists act as enhancers of stem cells in protecting cardiac myocyte survival from oxidative stress damage.
CSN20563 BMS-823778 hydrochloride 1140898-87-8 BMS-823778 is an orally available potent and selective inhibitor of 11-β-hydroxysteroid-dehydrogenase 1 (11βHSD-1). BMS-823778 is an antihyperglycaemic that may be a potential candidate for Type 2 diabetes treatment.
CSN20545 Evogliptin tartrate 1222102-51-3 Evogliptin tartrate is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor) which improves insulin resistance and delays the onset of diabetes.
<< PREV 1 2 3 4 5 6 7 8 9 NEXT >>
联系
我们